Aperio Group LLC Has $14.32 Million Holdings in Quest Diagnostics Incorporated (NYSE:DGX)

Aperio Group LLC lessened its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 2.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 125,031 shares of the medical research company’s stock after selling 2,718 shares during the period. Aperio Group LLC owned about 0.09% of Quest Diagnostics worth $14,315,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in DGX. Nuveen Asset Management LLC lifted its holdings in shares of Quest Diagnostics by 134.1% during the 2nd quarter. Nuveen Asset Management LLC now owns 1,718,572 shares of the medical research company’s stock worth $195,849,000 after acquiring an additional 984,331 shares during the period. Ceredex Value Advisors LLC bought a new stake in shares of Quest Diagnostics during the 2nd quarter worth approximately $65,242,000. Nordea Investment Management AB lifted its holdings in shares of Quest Diagnostics by 275.6% during the 2nd quarter. Nordea Investment Management AB now owns 618,806 shares of the medical research company’s stock worth $68,446,000 after acquiring an additional 454,048 shares during the period. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Quest Diagnostics by 72.0% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 967,288 shares of the medical research company’s stock worth $109,711,000 after acquiring an additional 405,024 shares during the period. Finally, Balyasny Asset Management LLC bought a new stake in shares of Quest Diagnostics during the 2nd quarter worth approximately $43,786,000. Hedge funds and other institutional investors own 87.23% of the company’s stock.

DGX opened at $122.90 on Tuesday. Quest Diagnostics Incorporated has a twelve month low of $73.02 and a twelve month high of $131.81. The company has a quick ratio of 1.32, a current ratio of 1.40 and a debt-to-equity ratio of 0.62. The company has a fifty day moving average of $120.58 and a 200-day moving average of $116.89. The stock has a market cap of $16.56 billion, a PE ratio of 15.19, a price-to-earnings-growth ratio of 1.40 and a beta of 1.18.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings data on Thursday, October 22nd. The medical research company reported $4.31 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.75 by $0.56. Quest Diagnostics had a net margin of 13.22% and a return on equity of 19.23%. The company had revenue of $2.79 billion during the quarter, compared to analysts’ expectations of $2.71 billion. During the same period in the prior year, the company posted $1.76 earnings per share. Quest Diagnostics’s revenue for the quarter was up 42.6% compared to the same quarter last year. Sell-side analysts anticipate that Quest Diagnostics Incorporated will post 9.99 EPS for the current fiscal year.

A number of brokerages have recently weighed in on DGX. Wells Fargo & Company reaffirmed a “hold” rating on shares of Quest Diagnostics in a report on Friday, October 23rd. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Quest Diagnostics from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Citigroup increased their price objective on shares of Quest Diagnostics from $130.00 to $151.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Argus raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating and set a $135.00 price objective for the company in a research note on Wednesday, October 21st. Finally, Mizuho increased their price objective on shares of Quest Diagnostics from $144.00 to $149.00 and gave the company a “buy” rating in a research note on Monday, October 26th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Quest Diagnostics has an average rating of “Hold” and a consensus target price of $126.83.

In other Quest Diagnostics news, CEO Stephen H. Rusckowski sold 291,997 shares of the firm’s stock in a transaction on Friday, October 16th. The shares were sold at an average price of $120.00, for a total value of $35,039,640.00. Following the completion of the sale, the chief executive officer now directly owns 529,744 shares in the company, valued at $63,569,280. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Michael J. Deppe sold 10,450 shares of the firm’s stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $125.00, for a total transaction of $1,306,250.00. Following the completion of the sale, the chief accounting officer now owns 29,785 shares of the company’s stock, valued at $3,723,125. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 396,430 shares of company stock valued at $47,039,374. 1.49% of the stock is currently owned by corporate insiders.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

See Also: Marijuana Stocks

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.